Collection : Essential
Last update : 12/06/2023
Price : 600 €
Number of pages : 23 pages
Language : English
Format : PDF (immediate availability)
Reference : 23XENT31
IN THIS XERFI GLOBAL REPORT :
WHAT IS THE GROUP'S FINANCIAL SITUATION ?
The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.
WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?
Rationalise chemical portfolio to focus on high-performance activities
Rebuild pharma line-up following Latuda patent expiry
Drive Crop Science growth with regenerative agriculture
WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?
Through a SWOT analysis, this report also provides an overview of the group's strengths (very diversified asset portfolio reduces impact of industry cycles, etc.) and weaknesses (plummeting Pharmaceuticals revenues and profitability following expiry of patent protections for Latuda, etc.).
Presentation
Segments
SWOT
INSCRIPTION NEWSLETTER SECTORIELLE
XREPORT ADDED TO BASKET
WHY A COOKIE?Continue without accepting >
The XERFI group uses and stores non-sensitive information obtained by placing cookies or equivalent technology on your device. The use of this data allows us to measure our audience and to offer you personalized features and content. We want to ensure that we provide the most informative experience for our visitors.
The data stored by XERFI is not shared with partners or resold to third-parties for advertising purposes. You can give, refuse or withdraw your consent at any time by accessing our cookie page.
EASILY CUSTOMIZE YOUR DATA STORAGE
You are free to modify your consent at any time by accessing our cookie setting tool.